Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Are you a print subscriber? Activate your account. By Ad Age Studio 30 - 1 day 13 hours ago By Ad Age Staff - 1 day 15 hours ago By Ad Age and Creativity Staff - 1 day 17 hours ago 1 day 19 hours ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.95 which represents a slight increase of $0.50 or 0.90% from the prior close of $55.45. The stock opened at ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, sending shares higher in pre-market trading. Concurrently, Merck & Co ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

PRINCETON, N.J., October 28, 2024--Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 PRINCETON, N.J., October 03, 2024--U.S. FDA ...